Researchers at Singapore's A*STAR Genome Institute have developed a new AI-based method called Fragle that can detect even the tiniest traces of cancer in a patient's blood.
Unlike traditional liquid biopsy techniques that require expensive, targeted gene sequencing, Fragle uses a low-cost approach that analyzes the fragment sizes of cell-free DNA—a subtle clue that can indicate the presence of tumor DNA (ctDNA).
Cancer-derived DNA fragments tend to be shorter and follow distinct patterns, which Fragle can detect using shallow whole-genome sequencing and machine learning.
This technique stands out because it's fast, highly sensitive, and affordable, costing less than SGD $50 per test compared to traditional methods that often exceed SGD $1,000.
It also doesn’t depend on knowing the specific mutations of a patient’s cancer, making it more universally applicable across cancer types.
Fragle could revolutionize cancer care by enabling frequent, non-invasive monitoring of cancer progression, recurrence, or response to treatment.
However, it still requires extensive clinical validation before it can be widely adopted in real-world healthcare settings.
Unlike traditional liquid biopsy techniques that require expensive, targeted gene sequencing, Fragle uses a low-cost approach that analyzes the fragment sizes of cell-free DNA—a subtle clue that can indicate the presence of tumor DNA (ctDNA).
Cancer-derived DNA fragments tend to be shorter and follow distinct patterns, which Fragle can detect using shallow whole-genome sequencing and machine learning.
This technique stands out because it's fast, highly sensitive, and affordable, costing less than SGD $50 per test compared to traditional methods that often exceed SGD $1,000.
It also doesn’t depend on knowing the specific mutations of a patient’s cancer, making it more universally applicable across cancer types.
Fragle could revolutionize cancer care by enabling frequent, non-invasive monitoring of cancer progression, recurrence, or response to treatment.
However, it still requires extensive clinical validation before it can be widely adopted in real-world healthcare settings.
Researchers at Singapore's A*STAR Genome Institute have developed a new AI-based method called Fragle that can detect even the tiniest traces of cancer in a patient's blood.
Unlike traditional liquid biopsy techniques that require expensive, targeted gene sequencing, Fragle uses a low-cost approach that analyzes the fragment sizes of cell-free DNA—a subtle clue that can indicate the presence of tumor DNA (ctDNA).
Cancer-derived DNA fragments tend to be shorter and follow distinct patterns, which Fragle can detect using shallow whole-genome sequencing and machine learning.
This technique stands out because it's fast, highly sensitive, and affordable, costing less than SGD $50 per test compared to traditional methods that often exceed SGD $1,000.
It also doesn’t depend on knowing the specific mutations of a patient’s cancer, making it more universally applicable across cancer types.
Fragle could revolutionize cancer care by enabling frequent, non-invasive monitoring of cancer progression, recurrence, or response to treatment.
However, it still requires extensive clinical validation before it can be widely adopted in real-world healthcare settings.
